Ipsen Completes Key Liver-Function Study for Palovarotene, Trimming Risk for Investors

Ipsen (GB:0MH6) announced an update on their ongoing clinical study.

Ipsen has completed a Phase I study called “A Phase I, Open-label, Parallel-group Study to Evaluate the Single-dose Pharmacokinetics of Palovarotene in Male and Female Participants With Moderate and Severe Hepatic Impairment and Matched Participants With Normal Hepatic Function.” The goal was to see how a single dose of palovarotene behaves in people with liver problems versus healthy adults, and what that might mean for safety.

The study tested palovarotene, an oral drug given as a one-time dose of up to 10 mg. It is designed to treat rare bone disorders, and this study looks at how to dose it safely in patients whose livers do not work normally.

The trial was interventional and early stage, with participants randomly placed into parallel groups. It was open-label, so both doctors and participants knew they were getting palovarotene, and the main aim was to understand how the body handles the drug rather than to measure clinical benefit.

Participants were split into three groups with different liver function levels, from normal to severe impairment. Blood samples and safety checks were done over 10 days to see how fast the drug moved through the body and to track any side effects.

The study was first submitted in March 2025, marking the formal launch of the work. The latest update was filed on February 27, 2026, confirming that the study status is now “completed,” which signals to investors that data collection is done and analysis is in progress.

This timing is important because it moves palovarotene a step closer to refined dosing and wider label use if results are supportive. Any clear guidance on dosing in liver-impaired patients could strengthen Ipsen’s rare disease portfolio and improve the asset’s risk profile in the eyes of the market.

For investors, this completed Phase I liver-impairment study reduces one key uncertainty around safety and dosing. That can help underpin valuation for Ipsen relative to rare disease peers, even though headline stock moves may wait for fuller results and any regulatory feedback.

Competitors in rare bone and skeletal disorders, including other mid-cap biopharma names, are also trying to de-risk their pipelines with similar early safety work. Ipsen’s progress here may support investor confidence that it can manage complex patient groups and sustain long-term revenue from palovarotene.

The trial is now listed as completed and recently updated, and investors can track further details and forthcoming results on the ClinicalTrials portal.

To learn more about GB:0MH6’s potential, visit the Ipsen drug pipeline page.